Explore KEYTRUDA® patient profiles
Explore efficacy and safety profile results for KEYTRUDA® as adjuvant therapy in completely resected stage III melanoma with lymph nodes involvement.
Discover results from the KEYNOTE-054 trialExplore efficacy and safety profile results for KEYTRUDA® as adjuvant therapy in completely resected stage III melanoma with lymph nodes involvement.
Discover results from the KEYNOTE-006Explore efficacy and safety profile results for KEYTRUDA® as adjuvant therapy in completely resected stage III melanoma with lymph nodes involvement.
Discover results from the KEYNOTE-002BRAF=v-raf murine sarcoma viral oncogene homolog B1; CT=computed tomography; ECOG PS=Eastern Cooperative Oncology Group Performance Status.
†Fictitious patient profile. May not be representative of all patients.
References:
1. Merck Canada Inc. KEYTRUDA® Product Monograph. April 19, 2023.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Melanoma Cancer, version 3. 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
CA-OOC-00027